Welcome to EQL Pharma's Investor Pages!

We strive to have an open and proactive dialogue with our shareholders.

42.70 SEK

To Stock Graph

+0.50 (+1.18%)

Spotlight Stock Market

Annual Report 2022/2023Read Here

Interim Report Q3 2023/2024 (in Swedish)

Listen to CEO Axel Schörling present EQL Pharma's latest report (in Swedish)

Interim Report Q3 2023/2024

Press Releases

2024-03-14

Mellozzan[® ](melatonin) have gained marketing approval in the UK

EQL's key product Mellozzan[®] has now gained marketing approval by the Health Authorities in the UK, where it is to be provided to patients by EQL's license partner Medice Arzneimittel Pütter GmbH...

2024-02-16

Nomination committee for the 2024 Annual General Meeting

Regulatory

According to the resolution of the 2023 Annual General Meeting, the Nomination Committee shall be convened by the Chairman of the Board and consist of a representative of each of the three largest ...

2024-02-13

Interim Report April - December 2023

Regulatory

Growth and profitability despite large impact from the global antibiotics shortage and continued expansion of pipeline

Se all

EQL Pharma in Short

EQL Pharma is an entrepreneurial pharmaceutical company focusing on simplicity and efficiency at all levels of the value chain in order to be able to deliver cost-efficient medicines of highest quality to pharmacies and hospitals.